Fig. 3
Evaluation of the tibiotarsal joints of ceftriaxone-treated mice. a Tibiotarsal joint swelling in the ceftriaxone-treated mice compared with the untreated infected and uninfected mice. Number of analyzed joints: untreated infected (n = 8–20), uninfected (n = 8), and ceftriaxone-treated (n = 8–16). b In vivo uptake values of Gallium-68-labeled Siglec-9 motif containing peptide (68Ga-DOTA-Siglec-9) in the ceftriaxone-treated mice compared with the untreated infected and uninfected mice. Number of analyzed joints: untreated infected (n = 4–8), uninfected (n = 4), and ceftriaxone-treated (n = 4–8). *P < 0.05 for ceftriaxone-treated vs. uninfected, # P < 0.05 for ceftriaxone-treated vs. infected. SUV Standardized uptake value